Are mifepristone and misoprostol safe to use while breastfeeding?

Mifepristone and Misoprostol Safety During Breastfeeding

Both mifepristone and misoprostol are safe to use during breastfeeding, with mifepristone present in breast milk at very low levels (relative infant dose of 0.5-1.5%) and breastfeeding can continue in an uninterrupted manner.

Mifepristone During Breastfeeding

Evidence from FDA Labeling and Research

• Mifepristone is present in human milk but at minimal levels. The FDA label states that published data from 10 breastfeeding women who received a single 600 mg dose showed an estimated relative infant dose of only 0.5% 1.

• Research using the 200 mg dose shows even lower exposure. A study of 12 women found the highest calculated relative infant dose was 1.5%, with milk:serum ratios ranging from <0.013:1 to 0.042:1 on day 3 2.

• Milk concentrations peak early and decline rapidly. Mifepristone levels were highest in the first 12 hours after intake (ranging from undetectable to 0.913 micromol/L), then declined over 7 days, with the lowest levels following the 200 mg dose 2.

Clinical Recommendations

• Breastfeeding can continue without interruption when using mifepristone for medication abortion, particularly with the standard 200 mg dose 2.

• For long-term mifepristone use (such as for Cushing's syndrome), the FDA suggests women may consider pumping and discarding milk during treatment and for 18-21 days (5-6 half-lives) after the last dose, though this applies to chronic dosing where accumulation may occur 1.

• The developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for mifepristone, though the evidence supports safety for single-dose use 1.

Misoprostol During Breastfeeding

General Medication Safety Principles

• Most medications used by breastfeeding women are compatible with breastfeeding, with only a limited number contraindicated 3.

• The most comprehensive resource for medication safety during lactation is LactMed (Drugs and Lactation Database), published by the National Library of Medicine 3, 4.

Misoprostol-Specific Considerations

While the provided evidence does not contain specific guidelines on misoprostol and breastfeeding, the general principles indicate:

• Misoprostol is commonly used in combination with mifepristone for medication abortion and early pregnancy loss management 5.

• The medication regimen is safe and effective for outpatient treatment, with expected effects including cramping and bleeding 5.

Practical Management Algorithm

For medication abortion in breastfeeding women:

1. Counsel the patient that both medications are compatible with continued breastfeeding 2

2. Administer standard dosing: 200 mg mifepristone orally followed by 800 mcg misoprostol (buccally or vaginally) 5

3. Advise uninterrupted breastfeeding - no need to pump and discard milk 2

4. Manage expected side effects (cramping, bleeding, gastrointestinal symptoms) with NSAIDs like ibuprofen, which are safe during breastfeeding 3

5. Provide appropriate analgesia: Paracetamol and ibuprofen are first-line choices for breastfeeding women 3

Important Caveats

• The FDA labeling notes longer half-life with repeat dosing compared to single-dose use, potentially leading to greater exposure with chronic use 1

• Single-dose use for medication abortion represents the lowest risk scenario with well-established safety data 2

• Ensure proper follow-up to confirm complete abortion, as this is standard care regardless of breastfeeding status 5